Virus-fighting immune cells for transplant patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests giving special immune cells to patients who had a stem cell transplant and are at high risk for viral infections. The cells may help prevent or fight infections like CMV and EBV after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 50 years old
- You had a stem cell transplant from a donor who is not a sibling
- Your transplant used a special method to remove some immune cells (T-cell depletion) or included radiation
- You have had a second transplant or had graft-versus-host disease that needed high-dose steroids
- You have a suitable donor for these special cells
- Your organs are working well enough (liver, kidneys, heart, lungs) to safely receive the cells
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially prepared donor immune cells can fight stubborn viral infections that did not get better with standard treatment. It is for people who have had a stem cell transplant and are still struggling with viruses like CMV, EBV, or others.
This early-phase study tests whether giving donor immune cells (DLI) that have been “depleted” of a specific marker (CD45RA) can lower the chance of the leukemia/lymphoma coming back after a half-matched stem cell transplant. It’s meant to be preventive, not treatment for an active relapse.
This early-phase study tests a modified immune-cell treatment given after a haploidentical stem cell transplant (using a half-matched donor). It aims to reduce the immune attack complications while still helping prevent or control blood cancer return.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This trial is testing a new way to treat blood cancers that have come back after a stem cell transplant and haven't responded to standard donor cell therapy. The treatment uses special immune cells that are modified to avoid attacking the body, which may help fight the cancer without causing graft-versus-host disease.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.